Press Release

Nov, 01 2023

Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, and Biocartis are Dominating the Europe Kirsten Rat Sarcoma (KRAS) Market in 2020

Europe Kirsten Rat Sarcoma (KRAS) Market is expected to grow with the CAGR of 11.8% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @

Europe Kirsten Rat Sarcoma (KRAS) Market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Kirsten Rat Sarcoma (KRAS) market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In October 2018, Ilumina Inc had launched the True Sight Oncology 500. The liquid biopsy panel, is a comprehensive pan-cancer assay, which has been designed to identify and detect known and upcoming tumor biomarkers. The panel launched by the company were used for molecular testing of biomarkers in lung cancer, being implemented for precision oncology and strengthened the Oncology portfolio. It demonstrated a positive growth in the market.

Thermo Fisher Scientific Inc., is dominating player in Kirsten Rat Sarcoma (KRAS) market. The other key players existing in the market includes F. Hoffmann-La Roche Ltd, Biocartis, Illumina, Inc., Merck KGaA, Abbott, QIAGEN, Agilent Technologies, Inc., among others.

Europe Kirsten Rat Sarcoma (KRAS) MarketThermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc., headquartered in Massachusetts, U.S. was founded in 2006. The company engages in the development, manufacture, marketing and sale of medical devices. The company offers Laboratory Supplies, Laboratory Equipment, Laboratory Instruments, Clinical & Diagnostics, Chromatography & Mass Spectrometry, Cell Culture, Protein and Cell Analysis, Molecular Biology & Nucleic Acid Analysis, Sequence-Specific Nucleic Acid Products. The company has presence in North America, Europe, and Asia-Pacific. The company has various subsidiaries that are Smith & Nephew Argentina S.R.L.2 (Argentina), Smith & Nephew Pty Limited (Australia), Smith & Nephew Medical (Shanghai) Limited (China), Smith & Nephew S.A. de C.V. (Mexico), Smith & Nephew Limited1 (New Zealand) among others.

For instance,

  • In October 2020, Thermo Fischer Scientific Inc, had announced to extend its collaboration with Symphogen, to provide nnovative cancer treatments through optimization of protein characterization and quality monitoring mass spectrometry workflows. The companies can provide the biopharmaceutical industry with compliance ready mass spectrometer solutions to boost the drug delivery. It would deliver a positive growth in the market. 

F. Hoffman-La Roche Ltd.

F. Hoffman La Roche Ltd. headquartered in Basel, Switzerland and was founded in year 1886. The company is focused on development of innovative medicines and diagnostics tests that help patients live longer and better lives. The company offers Blood Safety, Clinical Chemistry & Immunochemistry, Companion Diagnostics, Custom Biotech, Diabetes Care, Lab Automation & Software Solution, Molecular Diagnostics, Point of Care, and Tissue Diagnostics. The company has wide global presence across the world as North America, Europe, Asia-Pacific, South America, Middle East and Africa. Genentech (U.S), Chugai Pharmaceutical Co. (Japan), ROCHE HOLDING (UK) LIMITED (UK), Roche (Philippines) Inc. (Philippines), Roche Chile Limitada (Chile) among others are the subsidiaries of the company.

For instance,

  • In November 2015, F. Hoffmann-La Roche Ltd announced that they had expanded molecular diagnostic assays by Cobas 4800. This system will improve the efficiency and flexibility that allows laboratories to deliver results for rapid clinical decisions. This has increase the demand for the product in the recent past and is expected to increase in the forecasted period.


Biocartis is headquartered in Mechelen, Belgium and was founded in 2007. The company is focused to offer rapid & easy molecular diagnostics solutions aimed on fast and accurate treatment decisions for oncology patients across the globe. The company offers products for Infectious Disease, Oncology, and Pharma. The company has wide global presence across Americas, Europe, Asia-Pacific, Middle East and Africa. The company has various subsidiaries such as Biocartis NV (Belgium), Biocartis US Inc. (U.S.) and others.

For instance,

  • In December 2017, Biocartis announced that they had signed the agreement with Amgen to develop a platform for CDx for colorectal cancer. Under this, the Idylla platform is being used to develop test for the drug and help Amgen bring this product in the market and synergistically contribute to Biocartis growth in the forecast period.

Client Testimonials